Neil P. Shah, MD, PhD
Patients with chronic myeloid leukemia(CML) who discontinue treatment on a tyrosine kinase inhibitor (TKI) may potentially achieve a durable treatment-free remission (TFR), according to long-term findings of clinical trials, including the ENESTop study.
In the study, patients with CML who sustained a deep molecular response for at least 2 years on second-line nilotinib (Tasigna) were taken off treatment. MR4.5
was determined as the response criteria to be eligible for TKI discontinuation. At a follow-up of 48 weeks, 57.9% of patients remained in TFR; after 96 weeks, 53.2% remained in TFR.
Nilotinib was restarted upon loss of major molecular response or confirmed loss of MR4.
... to read the full story